GlassScriptPhysician profile
Stephen D Campbell
NPI 1801893524
$19,660.04
in general payments reported to CMS, 2019-2025
54 companies · $1,670 in 2025
The $1,670 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,463 · 2021: $1,043 · 2022: $974 · 2023: $1,116 · 2024: $1,951 · 2025: $1,670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,736.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $9,577.75 | 2019-2025 | Sublocade |
| Astrazeneca Pharmaceuticals LP | $1,723.25 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,227.27 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $1,042.66 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Lilly USA, LLC | $600.13 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $580.91 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $407.95 | 2019-2024 | Spravato |
| Astellas Pharma US INC | $354.91 | 2019-2025 | Veozah |
| Braeburn INC. | $346.37 | 2023-2025 | Brixadi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $322.25 | 2019-2023 | Jardiance |
| Amgen INC. | $300.78 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $295.70 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $246.25 | 2019-2025 | Rexulti |
| Glaxosmithkline, LLC. | $197.65 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Sanofi-Aventis U.S. LLC | $159.83 | 2019-2024 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.